Delving into the Latest Updates on Amitriptyline Hydrochloride with Synapse

Overview

Basic Info

SummaryAmitriptyline Hydrochloride, a small molecule drug, is a reuptake inhibitor targets the monoamine transporters. Developed by Merck and first approved on April 7th, 1961, the drug is used to treat a range of conditions such as neuralgia, depressive disorder, and nocturnal enuresis. The drug works by preventing the reuptake of neurotransmitters, particularly serotonin and norepinephrine, which can lead to an increase in their concentration in the brain and subsequently enhance mood. Amitriptyline Hydrochloride is available in the form of oral tablets, which should only be used under the strict guidance of a healthcare provider. Patients must be aware of potential side effects such as dry mouth, constipation, and drowsiness, which can manifest in some individuals. The drug's administration should be closely monitored and individualized to ensure its safe and effective use. In conclusion, while Amitriptyline Hydrochloride presents an effective medication for managing certain neurological and mood disorders, patients must exercise caution and adhere to the recommended usage guidelines.

Drug Type

Small molecule drug

Synonyms

10,11-dihydro-5-(γ-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene, 10,11-dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-Δ5,γ-propylamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine

+ [25]

Target

NET x SERT

Action

inhibitors

Mechanism

NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors

Therapeutic Areas

Nervous System DiseasesUrogenital DiseasesOther Diseases+ [2]

Active Indication

NeuralgiaDepressive Disorder, MajorDepressive Disorder+ [5]

Inactive Indication

Bipolar DisorderErythromelalgia

Originator Organization

Merck & Co., Inc.

Active Organization

AlgoTherapeutix SAS

Changzhou Siyao Pharmaceuticals Co. Ltd.

Nichi-Iko Pharmaceutical Co., Ltd.

+ [1]

Inactive Organization

AstraZeneca Pharmaceuticals LP

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (07 Apr 1961),

Bipolar DisorderDepressive Disorder, Major

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)

Login to view timeline

Structure/Sequence

Molecular FormulaC20H24ClN

InChIKeyKFYRPLNVJVHZGT-UHFFFAOYSA-N

CAS Registry549-18-8

The goal of this clinical trial is to assess and compare the effect of amitriptyline and trifluoperazine in improving dyspeptic symptoms in patients with functional dyspepsia. It will also assess about the safety of drugs amitriptyline and trifluoperazine by recording the patient reported adverse events. The main questions it aims to answer are:
Does drug amitriptyline and trifluoperazine has any effect on patients with functional dyspepsia? What medical problems do participants have when taking drug amitriptyline and trifluoperazine? Researcher will compare drug amitriptyline and trifluoperazine to a control group taking standard first line treatment only.
Participants will:
Take drug amitriptyline 10 milligrams at night or trifluoperazine 1 milligrams twice daily every day for 8 weeks along with standard first line treatment. A third group will be taken as control arm who will be kept on standard first line treatment only for 8 weeks. After that all three groups will be kept only on standard first line treatment for an additional 4 weeks. They will visit the hospital 4 weekly, and their symptoms will be assessed by a 5-point Likert Scale at baseline, week 4, 8, and 12. Additionally, patient reported adverse events will be documented.

Start Date01 Jul 2025

Sponsor / Collaborator

Dhaka Medical College

RBR-10kn9x8f

/ Not yet recruitingPhase 2IIT

Evaluation of the association of Amitriptyline or Acmella Oleracea with Lidocaine and Prilocaine nanocapsules in topical anesthesia: randomized, crossover clinical trial

Start Date05 Oct 2024

Sponsor / Collaborator-

100 Clinical Results associated with Amitriptyline Hydrochloride

Login to view more data

100 Translational Medicine associated with Amitriptyline Hydrochloride

Login to view more data

100 Patents (Medical) associated with Amitriptyline Hydrochloride

Login to view more data

11,427

Literatures (Medical) associated with Amitriptyline Hydrochloride

31 Dec 2026·ANNALS OF MEDICINE

Comparative effects of pharmacological interventions in the prophylactic treatment of tension-type headache: systematic review and network meta-analysis

Review

Author: Zheng, Hui ; Hua, Can ; Li, Xin-Yu ; Pantila, Kulachai ; Chen, Bo-Zhu ; Xie, Chao-Rong ; Lin, Li ; Tao, Qing-Feng ; Wang, Zhen-Zhi ; Mou, Jian-Jiao

BACKGROUND:

Tension-type headache (TTH) is the most common neurological disorder. The comparative effect of pharmacological interventions for TTH prophylaxis remains unclear. We aimed to assess the comparative effects of pharmacological interventions in the prophylactic treatment of TTH.

METHODS:

Ovid Medline, Embase, and Cochrane were searched from inception to 12 December, 2025. Randomized controlled trials (RCTs) of medications compared to placebo or another medication for preventing TTH were included. The primary outcome was headache days per month. A Bayesian random-effect model was employed as the primary analysis of chronic TTH.

RESULTS:

Thirty-five RCTs were included, 33 (88.6%) RCTs involved chronic TTH patients, and 24 RCTs provided available data for meta-analysis. Amitriptyline 100 mg presented more reduction of monthly headache days than placebo at 4 and 8 weeks (4 weeks: MD -6.59, 95% CrI -11.22 to -0.64; 8 weeks: MD -6.14, 95% CrI -10.27 to -0.87). BTX-A 100 U can reduce monthly headache days (MD -3.79, 95% CrI -7.16 to -0.33). Amitriptyline 100 mg was the highest-ranked treatment for monthly headache days at 4 (SUCRA 0.85), 8 (SUCRA 0.85), and 24 (SUCRA 0.87) weeks; 12 weeks was lidocaine 25 ml (SUCRA 0.75). Amitriptyline 100 mg and BTX-A 500 U showed a higher adverse event rate than placebo.

CONCLUSION:

Amitriptyline 100 mg and BTX-A 100 U may be options to reduce monthly headache days in patients with chronic TTH. Given the low to very low certainty of evidence, high risk of bias, and high heterogeneity, more studies are needed.

TRIAL REGISTRATION:

PROSPERO (CRD42025639586).

01 Dec 2026·Current Pain and Headache Reports

Efficacy and Safety of Melatonin in Migraine Prophylaxis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Review

Author: Khatatbeh, Abdallah Ahmad ; Abbas, Abdallah ; Aldemerdash, Ahmed ; Abouelmagd, Moaz Elsayed ; Monteith, Teshamae S ; Allam, Salma ; Osman, Ahmed S A ; AlEdani, Esraa M ; Aldemerdash, Mohamed A

Abstract:

Background:

Migraine is a chronic, disabling brain disorder. Melatonin, a circadian regulator with anti-inflammatory and antinociceptive actions, has been proposed for migraine prevention. We evaluated the efficacy and safety of melatonin for prophylaxis.

Methods:

We systematically searched PubMed, Cochrane, Scopus, Embase, and Web of Science (September 29, 2024) for randomised controlled trials (RCTs) comparing melatonin with placebo or other active drugs. Outcomes were analysed as change from baseline to last follow-up using mean differences (MD) or risk ratios (RR) with 95% confidence intervals (CI).

Results:

Nine RCTs ( n = 788) were included. Versus placebo, melatonin reduced attack duration (MD -4.98 h; 95% CI -9.30 to -0.67; p = 0.02), headache days (MD -1.54 days; 95% CI -2.50 to -0.58; p < 0.01), headache severity (MD -2.08; 95% CI -2.91 to -1.26; p < 0.01), and analgesic use (MD -1.38; 95% CI -2.41 to -0.36; p < 0.01). Melatonin also increased the response rate (≥ 50% reduction in monthly headache frequency) (RR 1.38; 95% CI 1.11–1.70; p < 0.01) and improved sleep quality (PSQI: MD -1.64; 95% CI -2.85 to -0.42; p = 0.008) and disability (MIDAS: SMD − 4.07; 95% CI -5.45 to -2.69; p < 0.001). Compared with amitriptyline, melatonin was generally less effective for attack duration and severity, with no consistent advantage on analgesic use or response; however, melatonin showed a more favourable tolerability profile, including lower risk of sleepiness (RR 0.49; 95% CI 0.28–0.87; p = 0.01).

Conclusions:

Melatonin demonstrates benefits over placebo for reducing migraine burden and improving patient-reported outcomes, with a favourable safety profile. While amitriptyline remains more potent for several efficacy endpoints, melatonin represents a reasonable preventive option, particularly as an adjunct during titration of first-line agents. Further head-to-head trials with standardised dosing and longer follow-up are warranted.

01 Apr 2026·FORENSIC SCIENCE INTERNATIONAL

Development of a standardized routine workflow for entomological and toxicological analysis using larvae of two forensically relevant fly species (Diptera, Calliphoridae)

Article

Author: Wissenbach, Dirk K ; Siemon, Laura ; Niederegger, Senta

For more than four decades, no standardized study design or workflow has been established for systematic entomotoxicological research in forensic casework. This study aimed to develop a universal rearing protocol for fly larvae grown on drug-spiked tissue surrogate and a standardized workflow for the qualitative analysis of pharmacologically active compounds (PACs) in insects of different developmental stages. Larvae of Protophormia terraenovae and Lucilia sericata were reared on minced meat serving as tissue surrogate. First-instar larvae were transferred to minced meat spiked with diazepam, amitriptyline, pipamperone, or lamotrigine, each triturated with placebo tablets. Actively feeding and post-feeding third-instar larvae were soaked for 24 h in ethanol (30 mL, 70:30, v:v), and both the larvae and the soaking solution were analysed using LC-MS/MS. The larval extraction method was optimized by replacing pure acetonitrile with an acetonitrile-methanol mixture and introducing centrifugation at -10°C. PAC detection was achieved in both larvae and soaking solution, confirming the sensitivity and applicability of the method. The workflow was further validated using authentic postmortem case samples. These findings demonstrate that ethanol-soaked larvae can be used effectively for both toxicological and entomological analyses. Overall, this study provides a universal and standardized workflow that simplifies and strengthens the application of entomotoxicology in forensic casework.

40

News (Medical) associated with Amitriptyline Hydrochloride

28 Oct 2025

·www.businesswire.com

Wisp Launches Comprehensive Migraine Care Vertical, Innovating Category with First-Ever, Asynchronous Care

NEW YORK--(BUSINESS WIRE)--Wisp, the largest pure play women's telehealth company in the U.S., today announced the launch of a dedicated migraine care vertical, consisting of online consults, prescription medications, and ongoing follow-up to help patients manage and prevent migraines. Wisp’s migraine specialists, certified by the National Headache Foundation, create customized treatment plans, expanding access to affordable, convenient care for patients wherever they are. Migraines affect one in five women — occurring nearly three times as often in women as in men — yet timely access to care remains a major barrier. On average, patients wait 34 days to see a neurologist, and in some cases, more than 90 days. Wisp’s new offering enables patients to receive care in 72 hours or less. “Migraine care is the natural next step for Wisp,” said Monica Cepak, CEO of Wisp. “Only one in four adults with episodic migraines receive diagnosis and treatment, and our patients continue to ask for treatment options. We’re delivering on our promise, with diagnoses made online, to democratize access to care, breaking down barriers so women can enjoy more pain-free days without the long wait times or high costs.” Wisp’s migraine care program includes: Migraine Consults ($60): Initial consults repeat every 6 weeks until the patient is on a stable dose. Quarterly Check-Ins ($30): Once stabilized, patients check in every 3 months for prescription refills. Prescriptions for Immediate Relief: Imitrex (Sumatriptan), Maxalt (Rizatriptan), Zomig ODT (Zolmitriptan). Anti-Nausea Medications: Zofran ODT (Ondansetron), Reglan (Metoclopramide). Preventive Medications: Topamax (Topiramate), Toprol XL (Metoprolol XL), Elavil (Amitriptyline), Lexapro (Escitalopram), Paxil (Paroxetine), Effexor ER (Venlafaxine ER). Patients begin with a $60 consult, complete a short intake form, and upload brief videos to help diagnose and assess eligibility. From there, a licensed provider reviews their medical history and intake to recommend a treatment plan, which may include immediate relief, anti-nausea, or preventive medications. Prescriptions are then sent the same day to the patient’s local pharmacy, with no insurance needed. “Migraines can be incredibly disruptive, but they are also very manageable with the right treatment plan,” said Dr. Jennifer Peña, Chief Medical Officer at Wisp. “Our approach provides patients with timely access to providers, tailored treatment options, and ongoing support so they feel empowered to take control of their health.” This launch follows Wisp’s recent expansion of its weight care vertical, furthering the company’s mission to provide affordable and accessible care for women across all life stages. From sexual and reproductive health to at-home diagnostics, fertility, menopause, to weight care and now migraine management, Wisp is continuing to build the most comprehensive platform designed for the unique needs of women. About Wisp: Wisp is the largest pure play women’s telehealth provider in the U.S., serving more than 1.5 million patients nationwide. Offering discreet, online care and a comprehensive range of first-to-market products, Wisp addresses women’s health needs across every stage of life—from birth control to fertility, menopause, STI testing, and more. Recognized by Fast Company as one of the Most Innovative Companies of 2023 and by Inc. as Best in Business 2024, Wisp is majority-owned by WELL Health Technologies Corp. Visit hellowisp.com or follow @hellowisp on social media.

23 Oct 2025

·www.drugs.com

Some Antidepressants Linked to Weight, Heart Health Changes

THURSDAY, Oct. 23, 2025 — Antidepressants are widely used to treat depression and anxiety , but a new study finds that some of these medications can cause noticeable changes in weight, heart rate and cholesterol levels. The study, published Tuesday in The Lancet , analyzed data from more than 58,000 participants to compare 30 different antidepressants or a placebo for an average of eight weeks. Researchers found what they called “clinically significant” differences in how each medication affected the body’s metabolism and blood flow. For example, people taking maprotiline gained an average of 4 pounds, while nearly half of users of amitriptyline experienced some weight gain. In contrast, agomelatine was linked to an average weight loss of 5.5 pounds among 55% of participants. Heart rate changes also differed. Some drugs, like nortriptyline , increased heart rate by about 14 beats per minute, while fluvoxamine caused a decrease of around 8 beats per minute. Researchers emphasized that while these findings highlight important differences, antidepressants remain effective treatments for depression and anxiety . The results show the need for personalized prescriptions so that doctors can better match a drug to patient’s health needs. "We do know that these medications are life-saving and life-changing, but they can have variation from person to person depending on a person's metabolism, their age (and) what other medications they're on," psychiatrist Dr. Sue Varma told CBS News after reviewing the findings. She noted that untreated depression can also cause physical changes like weight gain or loss, so it’s important to “weigh the risks and the benefits” of starting medication. Varma added that doctors should discuss possible side effects with patients before prescribing antidepressants and regularly monitor for any changes. "Let's not cause panic, but these medications do have really important side effects," Varma told CBS News. Sources CBS News, Oct. 22, 2025

Clinical Result

28 Jul 2025

·www.globenewswire.com

NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01

TORONTO, July 28, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and AlgoTherapeutix SAS ("AlgoTx"), a clinical-stage biotechnology company developing first-in-class therapies for chemotherapy-induced peripheral neuropathy (CIPN) today announced they have entered into an agreement. Under this agreement, NetraMark will deploy its NetraAI platform to analyze patient-level data from AlgoTx’s ATX01 program. NetraAI’s unique technology will enable deep exploration of drug and placebo response variables, identification of responder personas, and delivery of enrichment strategies to inform the design of future ATX01 trials. AlgoTx has established itself as a forward-thinking innovator committed to improving the lives of patients suffering from CIPN, with non opioid solutions. The company’s decision to partner with NetraMark underscores its dedication to leveraging cutting-edge technologies to optimize trial design, with the goal of accelerating development timelines. NetraAI’s unique methodology goes beyond traditional AI and machine learning tools by identifying and characterizing highly specific patient personas, enabling sponsors like AlgoTx to reduce placebo response, improve signal detection, and enrich trial populations with the most responsive patients—all critical factors in driving trial success. "AlgoTx is a leader in bringing innovation to Complex Pain treatments," said Josh Spiegel, President of NetraMark. "Their decision to partner with us reflects the growing recognition that explainable, precision AI can unlock value from clinical datasets that conventional approaches overlook. We look forward to supporting their team in seeking to enhance trial design and accelerate progress for patients in need." "At AlgoTx, we are committed to integrating innovation at every stage of development to unlock new therapeutic possibilities for patients living with CIPN," said Stephane Thiroloix, Founder and Chairman of the Board of Directors. "This agreement reflects our commitment to applying best-in-class innovation at every stage of our pipeline to ensure we bring transformative therapies to patients as efficiently as possible." NetraMark’s work will include the development of customized AI models and interactive tools that allow the AlgoTx team to test hypotheses, vary clinical significance thresholds, and precisely characterize patient subpopulations. The collaboration will focus on generating validated, explainable, and regulator-ready insights to optimize future studies. About NetraMarkNetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+). For more NetraMark information, see the company’s website and follow NetraMark on LinkedIn. About AlgoTherapeutix (AlgoTx) AlgoTherapeutix (AlgoTx) is a clinical stage biotechnology company developing a targeted, first in class therapeutic for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline for use in chemotherapy-induced peripheral neuropathy (CIPN), an area of high unmet need associated with unbearable pain in patients’ extremities and for which there is currently no viable treatment options. ATX01 targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. Its topical administration has been designed to provide targeted relief from the excruciating pain in patients’ extremities from CIPN, which is caused by nerve degeneration and is a common side effect of cancer treatment, occurring in 68% of patients. ATX01 was granted FDA fast track development status in CIPN. The company has completed recruitment and supporting analysis of data of its international Phase 2 clinical trial of 276 patients with CIPN (the ‘ACT’ study). The company has seasoned leadership, with experience of bringing global products successfully to market, and is backed by an international board. AlgoTx raised a Series B round of EUR 20 million in 2023 and has raised EUR 35 million to date. AlgoTx has a consortium of investors including Relyens Innovation Santé / Turenne Capital, who led the Series B fund raise, along with UI Investissement, and angel investors. Historical investors include Bpifrance through its Innobio 2 fund and Omnes Capital. For more information, see the company’s website and follow AlgoTx on LinkedIn. Forward-Looking StatementsThis press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the potential capabilities of the NetraAI platform to explore drug and placebo response variables, identify responder personas, reduce placebo response, improve signal detection, more precisely characterize patient subpopulations, deliver strategies to inform and improve trial design, accelerate development timelines and generate validated, explainable and regulator-ready insights to optimize future studies which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management’s Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information. The CSE does not accept responsibility for the adequacy or accuracy of this release. Contact Information:Swapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549

Phase 2Fast Track

100 Deals associated with Amitriptyline Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00809	Amitriptyline Hydrochloride	N06AA09	DB00321

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Neuralgia	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	29 Feb 2016
Depressive Disorder	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	02 Nov 1961
Nocturnal Enuresis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	02 Nov 1961
Bipolar Disorder	United States	AstraZeneca Pharmaceuticals LP	07 Apr 1961
Depressive Disorder, Major	United States	AstraZeneca Pharmaceuticals LP	07 Apr 1961

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Erythromelalgia	Phase 2	United States	AlgoTherapeutix SAS	14 Jun 2023
Erythromelalgia	Phase 2	Germany	AlgoTherapeutix SAS	14 Jun 2023
Pain	Phase 2	Germany	AlgoTherapeutix SAS	14 Jun 2023
Neoplasms	Phase 2	United States	AlgoTherapeutix SAS	28 Feb 2023
Neoplasms	Phase 2	Belgium	AlgoTherapeutix SAS	28 Feb 2023
Neoplasms	Phase 2	Czechia	AlgoTherapeutix SAS	28 Feb 2023
Neoplasms	Phase 2	France	AlgoTherapeutix SAS	28 Feb 2023
Neoplasms	Phase 2	Italy	AlgoTherapeutix SAS	28 Feb 2023
Neoplasms	Phase 2	Poland	AlgoTherapeutix SAS	28 Feb 2023
Neoplasms	Phase 2	Spain	AlgoTherapeutix SAS	28 Feb 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00124306 (IC01, CTgov)	Phase 3	Cystitis, Interstitial	271	Amitriptyline (1 - Amitriptyline)	mykjrvzhfz(wdsekcahdl) = zcwjhrgkrz gfcsdpzawn (zfxmizybcm, qvvrjhtnob - tlqxbzpvoa) View more	-	07 Oct 2025
				Placebo (2 - Placebo)	mykjrvzhfz(wdsekcahdl) = iobntbcmos gfcsdpzawn (zfxmizybcm, cftmwdlxvx - cqvixnqjsx) View more
NCT05593614 (Biospace) Manual	Phase 2	Pain	-	ATX01	uziksrxcza(udshybfemx) = drgfniprca zmnghqtibl (akjvoqezkq ) View more	Negative	18 Mar 2025
				Placebo	-
UEGW2023	Not Applicable	-	-	Amitriptyline 10-30mg once daily	kvpedirywh(kvuicxvnya) = 46 (19.8%) patients discontinued amitriptyline (30 (12.9%) adverse events) and 59 discontinued placebo (25.5%) (20 (8.7%) adverse events). There were 5 serious adverse reactions (2 amitriptyline, 3 placebo) gwcfvsemfw (gwwsrgrsss )	-	15 Oct 2023
				Placebo
NCT02090998 (CTgov)	Phase 4	Migraine Disorders \| Headache	10	SPG Block with 5% Lidocaine gel+Amitriptyline (Amitriptyline / Elavil)	nzgqrlabjj(yrlgkvpwyb) = qrahkagtou wetlsrrxno (gnecxfrtxf, 0.5) View more	-	29 Dec 2021
				SPG Block with 5% Lidocaine gel+Amitriptyline (SPG Nerve Block With Lidocaine 5% Gel)	nzgqrlabjj(yrlgkvpwyb) = llbenhlfhr wetlsrrxno (gnecxfrtxf, 10.4) View more
NCT02552225 (CTgov)	Phase 2/3	Laryngitis	6	Amitriptyline (Amitriptyline)	kzwdnqcmxf(nfvmyoxoqz) = oceykfhbkz cahivwqspi (zoxlzhqrrq, 1.41) View more	-	29 Oct 2021
				Placebo (Placebo)	kzwdnqcmxf(nfvmyoxoqz) = zmhcfkklan cahivwqspi (zoxlzhqrrq, 2.08) View more
UEGW2020	Not Applicable	-	194	Amitriptyline	qybvsbdxvr(qqnrcenzsi) = prmzmzaufp ruilvyknly (ouapudevtx ) View more	Positive	01 Oct 2020
				Placebo	qybvsbdxvr(qqnrcenzsi) = qrsqbhhotx ruilvyknly (ouapudevtx ) View more
NCT03591458 (CTgov)	Phase 2	Hypoglycemia \| Diabetes Mellitus, Type 1 \| Unconsciousness ... View more	2	Amitriptyline (Amitriptyline)	meefrhqqze(dtdiglpevm) = qnzumjnoqz vytmeyyacn (ojnwmvpjib, wbktkcwlzd - nzlreuwkxg) View more	-	22 Jul 2019
				Placebo (Placebo)	meefrhqqze(dtdiglpevm) = pipcckjwjz vytmeyyacn (ojnwmvpjib, rrgstsykml - gcmkgqjwpd) View more
NCT03096444 (CTgov)	Phase 2	Pruritus	13	Lidocaine hydrochloride+Amitriptyline hydrochloride+Ketamine hydrochloride (Topical KeAmLi Combo)	yzabdglllm(gioxvqespn) = nnytzfalbg jwtfvtpsdh (zhrqqjjxfj, 29.00397851) View more	-	02 Jul 2019
				Ketamine Hydrochloride (Topical Ketamine)	yzabdglllm(gioxvqespn) = ypdftesdyz jwtfvtpsdh (zhrqqjjxfj, 30.11218341) View more
UEGW2018	Not Applicable	Dyspepsia	-	Fluoxetine	neqjzxuwyn(qalvoxnnbi) = gcicijmitx xtdhvrzndj (sjcydkmlay )	-	01 Oct 2018
				Flupenthixol melitracen	neqjzxuwyn(qalvoxnnbi) = czqybdzdzw xtdhvrzndj (sjcydkmlay )
NCT01856270 (CTgov)	Phase 2	Post-Traumatic Headache \| Brain Injuries, Traumatic \| Headache	50	Amitriptyline (Amitriptyline Immediate)	sgpqrcfibr = rvkbbgkktj rfupdknasr (ovtjkyhepx, rqmmrehgqs - vhywtgfqua) View more	-	22 Dec 2017
				Amitriptyline (Amitriptyline Delayed)	sgpqrcfibr = idcbnygjbf rfupdknasr (ovtjkyhepx, lqmuudmhmr - byfjrlfnrs) View more